Guest
Signals accepts guest blog posts on topics relevant to stem cells and regenerative medicine, as well as submissions for its Right Turn Friday feature. The opinions, accuracy, completeness and validity of any statements made in guest posts are the responsibility of the author only and not the editor of Signals or CCRM, publisher of Signals. The copyright of this content belongs to the author and any liability with regards to infringement of intellectual property rights remains with the author. To reach the publisher, email info(at)CCRM.ca
Posts by: Guest
Will there be another perfect storm?
With a comprehensive background in the life sciences, Stephanie Mattsson possesses depth of expertise in strategic venture development. She has experience from one of Sweden’s largest venture capital funds, as well as several years in management consulting. She currently holds a position at CCRM Nordic as Director of Venture Development where she has responsibility for […]
Analysis of investment patterns in regenerative medicine startups
Laya Kiani has a degree in Pharmaceutical Chemistry from the University of Guelph, which she combines with a keen passion for business and marketing. She has shifted her focus toward the business side of health care, driven by a desire to make significant impacts in the health science sector. Dedicated to continuous learning and professional […]
Thoughts on the future of artificial intelligence in health care and biomanufacturing
Meighan Atkinson is the Communications Coordinator at CCRM. Meighan recently completed her Honours Bachelor of Arts degree at the University of Toronto, majoring in Professional Writing & Communications. Through her studies and contributions to The Medium as Staff Writer, Meighan discovered an interest in science communications. Rarely do you read a news story about […]
“The Rhyme of the Untimely Investor,” – a private equity homage to the “Rime of the Ancient Mariner”
Phil Vanek is responsible for technical due diligence and evaluation of potential investments, as well as guiding operational, R&D and strategic initiatives carried out at portfolio companies. An entrepreneurial and strategic international business leader, Phil joins Gamma Biosciences from GE Healthcare’s Cell and Gene Therapy business unit where he directed strategy and portfolio growth. Phil received his […]